- Home
- IMCR vs SONO Comparison
IMCR vs SONO Comparison
Compare IMCR & SONO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- SONO
- Stock Information
- Founded
- IMCR 2008
- SONO 2002
- Country
- IMCR United Kingdom
- SONO United States
- Employees
- IMCR N/A
- SONO N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- SONO Consumer Electronics/Video Chains
- Sector
- IMCR Health Care
- SONO Consumer Discretionary
- Exchange
- IMCR Nasdaq
- SONO Nasdaq
- Market Cap
- IMCR 1.6B
- SONO 1.2B
- IPO Year
- IMCR 2021
- SONO 2018
- Fundamental
- Price
- IMCR $35.05
- SONO $10.53
- Analyst Decision
- IMCR Buy
- SONO Buy
- Analyst Count
- IMCR 10
- SONO 3
- Target Price
- IMCR $58.13
- SONO $13.00
- AVG Volume (30 Days)
- IMCR 322.9K
- SONO 1.7M
- Earning Date
- IMCR 08-07-2025
- SONO 08-06-2025
- Dividend Yield
- IMCR N/A
- SONO N/A
- EPS Growth
- IMCR N/A
- SONO N/A
- EPS
- IMCR N/A
- SONO N/A
- Revenue
- IMCR $333,581,000.00
- SONO $1,463,138,000.00
- Revenue This Year
- IMCR $26.82
- SONO N/A
- Revenue Next Year
- IMCR $8.15
- SONO $3.27
- P/E Ratio
- IMCR N/A
- SONO N/A
- Revenue Growth
- IMCR 25.75
- SONO N/A
- 52 Week Low
- IMCR $23.15
- SONO $7.63
- 52 Week High
- IMCR $41.54
- SONO $15.89
- Technical
- Relative Strength Index (RSI)
- IMCR 58.09
- SONO 49.31
- Support Level
- IMCR $32.20
- SONO $10.38
- Resistance Level
- IMCR $35.69
- SONO $11.12
- Average True Range (ATR)
- IMCR 1.29
- SONO 0.39
- MACD
- IMCR 0.29
- SONO -0.04
- Stochastic Oscillator
- IMCR 81.93
- SONO 14.85
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa and the Asia Pacific. Generating a majority of its revenue from the Americas.